Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 50 years old~* Asian ethnicity~* Group 1: Cognitively intact healthy volunteers defined by Cumulative Illness Rating Scale for Geriatrics rating of ≤ 2 for all categories except for the category psychiatric illness which should have a rating of 0 and a CDR of 0 within 1 year prior to the visit.~OR~Group 2a: AD patients clinically diagnosed with mild AD (according to the National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria (McKhann et al., 1984)) with Clinical Dementia Rating-1~OR~Group 2b: AD patients clinically diagnosed with moderate AD (according to the National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria (McKhann et al., 1984)) with Clinical Dementia Rating-2~- Written informed consent provided according to local regulations.~Exclusion Criteria:~* Group 1 only: Current diagnosis of AD or other dementias according to National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria (McKhann et al.,1984 )~* Group 2 only: Change in dose within 2 months prior to visit of AD medication (e.g. donepezil, rivastigmine, galantamine or memantine)~Group 1 and 2:~* Diagnosis of significant neurological disease (for Groups 2a and 2b: other than AD), including vascular dementia according to National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria, cerebral tumour, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, seizures, major depression, schizophrenia and other entities~* Use of vitamins supplements (only vitamins supplements C and D are allowed) for 3 months prior to the visit~* Use of vitamin B injections~* Alcohol or drug abuse as per investigator's judgement~* Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements~* Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mild and Moderate Alzheimer's Disease (Type: None): None
- Cognitively intact healthy people (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).